Insulin Resistance and Oxidative Stress in Children Born Small and Large for Gestational Age
Increased IR and oxidative stress are already present in prepubertal normal-weight SGA and LGA children with a continuous alteration in relation to obesity, suggesting that BW and adiposity represent 2 independent risk factors for degenerative diseases (Pediatrics)
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
Among older patients with diabetes, pioglitazone is associated with a significantly lower risk of heart failure and death than is rosiglitazone. Given that rosiglitazone lacks a distinct clinical advantage over pioglitazone, continued use of rosiglitazone may not be justified (BMJ)
Rosiglitazone or pioglitazone in type 2 diabetes?
Longer term safety data are needed before a change in practice is warranted (Editorial BMJ, UK]
Insulin-treated diabetes in Australia 2000-2007
This report shows that the incidence of Type 1 and other insulin-treated diabetes in Australia is increasing and people with insulin-treated diabetes have significantly higher death rates than other Australians (AIHW, Australia)
Glycemic Control in Youth with Diabetes: The SEARCH for Diabetes in Youth Study
The high percentage of US youth with HbA1c levels above the target value and with poor glycemic control indicates an urgent need for effective treatment strategies to improve metabolic status in youth with diabetes (Journal of Pediatrics)
A cohort study of the risk of cancer associated with type 2 diabetes
Significantly increased risks were observed for pancreatic, liver and colon cancer (British Journal of Cancer)
Takeda Reacquires Canadian Rights to Leading Diabetes Drug from Eli Lilly Canada
Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. (BioSpace)
Glycosmedia is also available as an App: